Clinical Trials

Clinical Trials

Office of Psychiatric Clinical Research
Division of Behavioral Neurobiology

Purpose of the Office of Psychiatric Clinical Research: To support psychiatric research in the clinical setting

Research Staff:
Roberta May, MA, CCRC - Director
Hollis Reeves, BS, CCRC - Clinical Trials Administrator
Rakesha Garner, BS - Project Coordinator

The Office of Psychiatric Clinical Research offers the following resources for Phase II, III and IV studies:
• Coordination of the highest quality of clinical trials
• Experienced investigators and staff dedicated to academic excellence and quality patient care
• Full-time clinical research staff
• Regulatory and administrative services
• Assistance in designing clinical studies and providing referrals for statistical analysis
• Investigator training in psychiatric rating scales and standardized diagnostic instruments
• Expertise in patient recruitment
• Quality Assurance Program
• Facilities for drug storage, physical exams, EKG's, interviewing, venipuncture and specimen processing

Research Projects: Clinical Trials Currently Enrolling Participants

1. GSK-3 Study: The purpose of this study is to test the changes of an enzyme, glycogen synthase kinase-3, in the blood cells of individuals with either Bipolar Disorder or Major Depressive Disorder before and after treatment with medications for mood disorders. (Principal Investigator: Xiaohua Li, M.D., Ph.D.) Study Coordinator: Rakesha Garner (205) 934-9189

2. Adult ADHD + Insomnia: This is an 8 week, randomized double-blind, placebo controlled crossover trial of Ramelteon in adult ADHD subjects who suffer from initial insomnia. The purpose of this study is to evaluate the effectiveness of Ramelteon compared to placebo on sleep latency, sleep-onset, and total sleep time measures in adults with ADHD. (Principal Investigator: Rachel Fargason, M.D.) Study Coordinator: Rakesha Garner (205) 934-9189

3. Alzheimer's Disease: The purpose of this study is to evaluate the effect of multiple doses of intravenously administered bapineuzumab on biomarkers that may be indicative of disease modification in subsets of patients with mild to moderate Alzheimer's Disease versus placebo. (Principal Investigator: F. Cleveland Kinney, M.D., Ph.D., Sub-Investigator: Daniel Dahl, M.D.)
Study Coordinator: Hollis Reeves 205-975-0068

4. Adolescent Schizophrenia: The purpose of this study is to evaluate the safety and tolerability of oral ziprasidone compared to placebo in the treatment of adolescent subjects, ages 13-17, with schizophrenia. (Investigators: James Cullinan, D.O., Laura Montgomery-Barefield, MD, and Lee Tolbert, PhD) Study Coordinator: Roberta May (205) 934-2605

Studies Currently in Follow-up

1. Autism: The purpose of the study is to look at the safety and effectiveness of different doses of Aripiprazole compared to placebo in children and adolescents, ages 6 to 19, with autistic disorder. (Investigators: Latamia White, MD, Laura Montgomery-Barefield, MD, Tolulope Aduroja, MD, Suneel Katragadda, MD, and Lee Tolbert, PhD)

For further information, please contact:

UAB Department of Psychiatry

Office of Psychiatric Clinical Research

1700 Seventh Avenue South

Birmingham, AL 35294

Telephone (205) 934-2605 or (205) 934-2484